Literature DB >> 25774849

Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome.

Gabriele Deidda1, Martina Parrini1, Shovan Naskar1, Ignacio F Bozarth1, Andrea Contestabile1, Laura Cancedda1.   

Abstract

Down syndrome (DS) is the most frequent genetic cause of intellectual disability, and altered GABAergic transmission through Cl(-)-permeable GABAA receptors (GABAARs) contributes considerably to learning and memory deficits in DS mouse models. However, the efficacy of GABAergic transmission has never been directly assessed in DS. Here GABAAR signaling was found to be excitatory rather than inhibitory, and the reversal potential for GABAAR-driven Cl(-) currents (ECl) was shifted toward more positive potentials in the hippocampi of adult DS mice. Accordingly, hippocampal expression of the cation Cl(-) cotransporter NKCC1 was increased in both trisomic mice and individuals with DS. Notably, NKCC1 inhibition by the FDA-approved drug bumetanide restored ECl, synaptic plasticity and hippocampus-dependent memory in adult DS mice. Our findings demonstrate that GABA is excitatory in adult DS mice and identify a new therapeutic approach for the potential rescue of cognitive disabilities in individuals with DS.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25774849     DOI: 10.1038/nm.3827

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  67 in total

1.  Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.

Authors:  Roman Tyzio; Romain Nardou; Diana C Ferrari; Timur Tsintsadze; Amene Shahrokhi; Sanaz Eftekhari; Ilgam Khalilov; Vera Tsintsadze; Corinne Brouchoud; Genevieve Chazal; Eric Lemonnier; Natalia Lozovaya; Nail Burnashev; Yehezkel Ben-Ari
Journal:  Science       Date:  2014-02-07       Impact factor: 47.728

2.  Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue.

Authors:  Yijun Li; Ryan Cleary; Mark Kellogg; Janet S Soul; Gerard T Berry; Frances E Jensen
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-02-19       Impact factor: 3.205

3.  Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome.

Authors:  Fabian Fernandez; Wade Morishita; Elizabeth Zuniga; James Nguyen; Martina Blank; Robert C Malenka; Craig C Garner
Journal:  Nat Neurosci       Date:  2007-02-25       Impact factor: 24.884

4.  The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects.

Authors:  Eric Lemonnier; Yehezkel Ben-Ari
Journal:  Acta Paediatr       Date:  2010-12       Impact factor: 2.299

5.  Lithium rescues synaptic plasticity and memory in Down syndrome mice.

Authors:  Andrea Contestabile; Barbara Greco; Diego Ghezzi; Valter Tucci; Fabio Benfenati; Laura Gasparini
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

6.  Bumetanide inhibits rapid kindling in neonatal rats.

Authors:  Andréy Mazarati; Don Shin; Raman Sankar
Journal:  Epilepsia       Date:  2009-02-26       Impact factor: 5.864

7.  Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study.

Authors:  Nouchine Hadjikhani; Nicole R Zürcher; Ophelie Rogier; Torsten Ruest; Loyse Hippolyte; Yehezkel Ben-Ari; Eric Lemonnier
Journal:  Autism       Date:  2013-12-16

8.  Treating Fragile X syndrome with the diuretic bumetanide: a case report.

Authors:  Eric Lemonnier; Gaëlle Robin; Céline Degrez; Roman Tyzio; Marine Grandgeorge; Yehezkel Ben-Ari
Journal:  Acta Paediatr       Date:  2013-06       Impact factor: 2.299

9.  Shank3 mutant mice display autistic-like behaviours and striatal dysfunction.

Authors:  João Peça; Cátia Feliciano; Jonathan T Ting; Wenting Wang; Michael F Wells; Talaignair N Venkatraman; Christopher D Lascola; Zhanyan Fu; Guoping Feng
Journal:  Nature       Date:  2011-03-20       Impact factor: 49.962

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  91 in total

1.  Increased Fibronectin Impairs the Function of Excitatory/Inhibitory Synapses in Hirschsprung Disease.

Authors:  Ni Gao; Peimin Hou; Jian Wang; Tingting Zhou; Dongming Wang; Qiangye Zhang; Weijing Mu; Xiaona Lv; Aiwu Li
Journal:  Cell Mol Neurobiol       Date:  2019-11-23       Impact factor: 5.046

2.  Decreasing the Expression of GABAA α5 Subunit-Containing Receptors Partially Improves Cognitive, Electrophysiological, and Morphological Hippocampal Defects in the Ts65Dn Model of Down Syndrome.

Authors:  Verónica Vidal; Susana García-Cerro; Paula Martínez; Andrea Corrales; Sara Lantigua; Rebeca Vidal; Noemí Rueda; Laurence Ozmen; Maria-Clemencia Hernández; Carmen Martínez-Cué
Journal:  Mol Neurobiol       Date:  2017-07-17       Impact factor: 5.590

3.  Impaired regulation of KCC2 phosphorylation leads to neuronal network dysfunction and neurodevelopmental pathology.

Authors:  Lucie I Pisella; Jean-Luc Gaiarsa; Diabé Diabira; Jinwei Zhang; Ilgam Khalilov; JingJing Duan; Kristopher T Kahle; Igor Medina
Journal:  Sci Signal       Date:  2019-10-15       Impact factor: 8.192

4.  A limited role of NKCC1 in telencephalic glutamatergic neurons for developing hippocampal network dynamics and behavior.

Authors:  Jürgen Graf; Chuanqiang Zhang; Stephan Lawrence Marguet; Tanja Herrmann; Tom Flossmann; Robin Hinsch; Vahid Rahmati; Madlen Guenther; Christiane Frahm; Anja Urbach; Ricardo Melo Neves; Otto W Witte; Stefan J Kiebel; Dirk Isbrandt; Christian A Hübner; Knut Holthoff; Knut Kirmse
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

5.  Impaired glucose tolerance, glucagon, and insulin responses in mice lacking the loop diuretic-sensitive Nkcc2a transporter.

Authors:  Lisa Kelly; Mohammed M Almutairi; Shams Kursan; Romario Pacheco; Eduardo Dias-Junior; Hayo Castrop; Mauricio Di Fulvio
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-31       Impact factor: 4.249

6.  Intracellular chloride accumulation: a possible mechanism for cognitive deficits in Down syndrome.

Authors:  Alberto C Costa
Journal:  Nat Med       Date:  2015-04       Impact factor: 53.440

7.  Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome.

Authors:  Sarah E Lee; Monica Duran-Martinez; Sabina Khantsis; Diana W Bianchi; Faycal Guedj
Journal:  Trends Mol Med       Date:  2019-11-07       Impact factor: 11.951

8.  The medial temporal memory system in Down syndrome: Translating animal models of hippocampal compromise.

Authors:  Caron A C Clark; Fabian Fernandez; Stella Sakhon; Goffredina Spanò; Jamie O Edgin
Journal:  Hippocampus       Date:  2017-03-27       Impact factor: 3.899

9.  Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Authors:  Alexander M Kleschevnikov; Jessica Yu; Jeesun Kim; Larisa V Lysenko; Zheng Zeng; Y Eugene Yu; William C Mobley
Journal:  Neurobiol Dis       Date:  2017-03-22       Impact factor: 5.996

10.  Neonatal inhibition of Na+-K+-2Cl--cotransporter prevents ketamine induced spatial learning and memory impairments.

Authors:  Ryan A Stevens; Brandon D Butler; Saurabh S Kokane; Andrew W Womack; Qing Lin
Journal:  Neurotoxicol Teratol       Date:  2016-11-05       Impact factor: 3.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.